Abstract: A method for the color retention of dyed keratin fibers is provided herein. The method includes i. applying a cosmetic composition to dyed keratin fibers as a pretreatment agent for keratin. The method further includes ii. subjecting the keratin fibers to a dyeing and/or brightening within a period of about 5 seconds to about 24 hours after to step i. The cosmetic composition has, based on its own weight, from about 0.01 to about 4.00% by weight of at least one alum and a pH value in the range of about 2.5 to about 5.

Abstract: A cosmetic having excellent properties in transparency, spreadability, smoothness, skin compatibility and safety is prepared using a synthetic talc that is flake-like particles containing 2:1-type laminar crystals of silicate which have a basic structure of an octahedron sheet sandwiched between two tetrahedron sheets. The flake-like particle has a mean volume particle diameter of 0.5 to 100 ?m, and 0.3° or less of half width at half maximum of peak present at 2? equal to 9.4°±1° when measured by unoriented powder X-ray diffractometry (XRD) using CuK? rays, and the cosmetic is substantially free of Mg3Si2O5(OH)4.

Abstract: A method for strengthening and repairing keratin fibres including providing a caustic as well as an acidic crosslinking composition, wherein the caustic crosslinking composition comprises an at least bi-functional Brønsted-base and the acidic crosslinking composition comprises an at least bi-functional organic acid, and a cosmetically acceptable carrier; applying the caustic as well as the acidic crosslinking composition to keratin fibres; and optionally mixing the caustic crosslinking composition into a commercially available hair colouring or hair bleaching composition.

Abstract: The present invention discloses new uses of coloured co-crystals and associated salts formed by co-crystallization reactions in the dye, ink and paint industries. The present invention also provides novel co-crystals for use in, for example, the dye, ink and/or paint industries.

Abstract: Described herein is a shampoo composition and methods of using the same, the shampoo composition including a copper chelant, a detersive surfactant, and a carrier.

Abstract: Described herein is a hair conditioner composition and methods of using the same, the hair conditioner composition including an effective chelant. The hair conditioner composition further includes one or more high melting point fatty compounds and a cationic surfactant.

Abstract: The present invention is directed to combination sunscreen and insect repellant compositions. The combination sunscreen and insect repellant compositions contain (i) diethyl toluamide (or N,N-Diethyl-3-methylbenzamide or DEET), and (ii) one or more sunscreen components, with each sunscreen component being capable of absorbing ultraviolet light rays. The combination sunscreen and insect repellant compositions may contain additional composition components such as a polymeric binder system, and deionized water. The present invention is also directed to methods of making and using combination sunscreen and insect repellant compositions.

Abstract: The present disclosure relates to antiperspirant cosmetic agents, in the case of which the total amount of antiperspirant compounds can be clearly reduced without the antiperspirant effect of said agents or the storage stability of said agents being impaired, comprising—in each case with respect to the total weight of the antiperspirant cosmetic agent—a) 1 to 30 wt % of at least one antiperspirant compound, b) 0.1 to 10 wt % of salicylic acid, c) at least one compound of formula (I), in which n represents 0 or 1, X represents —H, Na+, K+, or NH4+, R1 is selected from —H, —COOX, or —(CH2)—COOX, R2 is selected from —H, C1-10 alkyl, or COOX, R3 is selected from —(CH2)—COOX, —(CH2)2-N[(CH2)—COOX]2, —CH(R1)—COOX, —(CH2)2-NH[CH(COOX)(CH2COOX)], —CH(R4)—C(R5)(R6)—COOX, R4 is selected from —H, C1-10 alkyl, or COOX, and R5 and R6 are, independently of each other, —H, —OH, or C1-10 alkyl.

Abstract: Provided is a cleansing composition of acyl amino acid, showing good foamability and good lather retention effect, which is rinsed off quickly and affords superior skin texture after drying. A cleansing composition containing the following components (A), (B) and (C), wherein a weight ratio of (A)/(B) is 0.2-5 and a weight ratio of ((A)+(B))/(C) is 2.5-10.0: (A) N-lauroylglycine or a salt thereof (B) N-myristoylglycine or a salt thereof (C) N-acyl acidic amino acid having an acyl group having 8-24 carbon atoms, or a salt thereof.

Abstract: The present invention relates to a composition that acts prior to the action of a tooth whitening composition or tooth whitening patch, the composition containing an oral cavity stimulation alleviating component able to reduce stimulation by the tooth whitening composition or patch. The present invention also relates to a tooth whitening kit whereby oral cavity stimulation is alleviated. The composition that acts prior to the action of a tooth whitening composition or patch of the present invention provides an outstanding tooth whitening effect while alleviating pain by mitigating intra-oral stimulation brought about by the rapid action of a tooth whitening component due to a tooth whitening component active agent.

Abstract: Compositions that include at least one potassium-containing amphoacetate and/or betaine surfactant, water and at least one additional surfactant selected from anionic surfactants, cationic surfactants, non-ionic surfactants, zwitterionic surfactants, and mixtures thereof.

Abstract: The invention relates to a cosmetic composition comprising one or more pyridinedicarboxylic acid derivatives of general formula (I) or a salt thereof and one or more antioxidants chosen from flavone heterosides, polyhydroxylated stilbenes, pyrimidinecarboxylic acid derivatives and ascorbic acid esters.

Abstract: Described herein is a shampoo composition and methods of using the same, the shampoo composition including a Class I and/or Class II chelant, a detersive surfactant, and a carrier.

Abstract: Described herein is a hair conditioner composition and methods of using the same, the hair conditioner composition including an effective chelant. The hair conditioner composition further includes one or more high melting point fatty compounds and a cationic surfactant.

Abstract: A hair care composition that removes calcium fatty carboxylate salts from the hair and scalp is provided. The hair care composition includes a calcium chelant, an anionic surfactant, a hydrotrope, a carrier, and optionally a zwitterionic surfactant.

Abstract: A moisturizing base material that contains a lipid peptide compound including at least one of compounds of Formula (1) below and simulated compounds thereof or pharmaceutically usable salts thereof, a surfactant, a specific polyhydric alcohol, a fatty acid, and water. (wherein R1 is a C9-23 aliphatic group; R2 is a hydrogen atom or a C1-4 alkyl group that optionally has a branched chain having a carbon atom number of 1 or 2; and R3 is a —(CH2)n—X group; n is a number of 1 to 4; and X is amino group, guanidino group, —CONH2 group, or a 5-membered cyclic group optionally having 1 to 3 nitrogen atoms, a 6-membered cyclic group optionally having 1 to 3 nitrogen atoms or a condensed heterocyclic group constituted by a 5-membered cyclic group and a 6-membered cyclic group which optionally have 1 to 3 nitrogen atoms.

Abstract: The peptidic compound comprises at least an aminoacid which is lysine, ornithine, diaminopropionic acid or diaminobutyric acid or a derivative of these aminoacids, on which a carboxylic acid is grafted via a peptidic bound on the nitrogen of the lateral chain, said carboxylic acid comprising a (poly)cycle or (poly)heterocycle. Preferably, the grafted carboxylic acid is an aminoacid or a derivative, in particular selected from, a proline, a hydroxyproline or pyroglutamic acid. The peptidic compound can stimulate the synthesis of the main molecules constituting the extracellular matrix of the skin, especially collagen 1 and 4 and elastin. It can be used for topical cosmetic treatment such as a global anti-aging treatment, or for specific activities, including anti-wrinkles, moisturizing, to improve the mechanical properties of the skin, firmness/tone/elasticity/flexibility, to increase density and volume of the skin, improve skin radiance, for a restructuring effect and/or to fight stretch marks.

Abstract: Hair cleansing conditioners which include—in relation to the weight of the total composition— a) from about 0.0001 to about 10 wt. % of a cationic 3-acrylamidopropyl trimethylammonium salt homopolymer, and b) from about 0.01 to about 20 wt. % of at least one non-ionic surfactant and/or at least one amphoteric surfactant are exemplified by an excellent cleansing and conditioning effect. Hair treated with the hair cleansing conditioners has volume and fullness even after repeated use. There is no weighing-down of the hair (no build-up effect). In addition, treated hair has an improved feel and improved styling properties and improved combability. Such hair cleansing conditioners can also be easily rinsed out from the hair.

Abstract: The present invention is in the field of personal care compositions; in particular skin lightening compositions. A composition that combines the cyclic adenylic acid reduction and the reduction of melanin content in melanocytes remains to be desired. It has been found that niacinamide in combination with MMP inhibitor galardin synergistically reduces melanin content in melanocytes. The invention thus relates to a composition comprising a synergistic combination of niacinamide and galardin for use in skin lightening. Thus the composition, when applied topically over an appropriate length of time in-vivo, may be used to lighten the skin, or to reduce age spots or freckles.

Abstract: A crosslinkable coating composition comprising: ingredient A that has at least two protons that can be activated to form a Michael carbanion donor; ingredient B that functions as a Michael acceptor having at least two ethylenically unsaturated functionalities each activated by an electron-withdrawing group; and a dormant carbamate initiator of Formula (1) wherein R1 and R2 can be independently selected from hydrogen, a linear or branched substituted or unsubstituted alkyl group having 1 to 22 carbon atoms; 1 to 8 carbon atoms; and An+ is a cationic species or polymer and n is an integer equal or greater than 1 with the proviso that An+ is not an acidic hydrogen; and optionally further comprising ammonium carbamate (H2NR1R2+?OC?ONR1R2). The crosslinkable coating composition can be used for a variety of coating applications including nail coating compositions.

Abstract: An anhydrous topical composition provides a water repellent surface. The anhydrous topical composition has at least one film former with surface tension lower than 35 dynes/cm, at least one particle having a hydrophobic surface or a hydrophobic surface treatment, and a volatile topical carrier.

Abstract: Disclosed is a cosmetic or dermatological preparation which comprises one or more extracts of Saxifraga oppositifolia (purple saxifrage) and/or one or more extracts of Soldanella alpina (alpine snowbell). The use of these extracts to combat extrinsic and intrinsic skin aging is likewise described.

Abstract: Topical compositions, packaging systems and methods for improving the appearance of skin or at least one sign of aging in skin including Kachnar are described.

Abstract: Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided.

Abstract: Orally dissolving films including a pharmaceutically active ingredient having a low bioavailability due to first-pass metabolism and/or low water solubility upon oral administration and a pharmaceutically acceptable excipient, and a medical application thereof.

Abstract: The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.

Abstract: An inhaler-delivery-device-packaged homogenate of solid heterogeneous-lipid particulates carrying lipophilic cannabinoid receptor agonists and/or antagonists, wherein the solid heterogeneous-lipid particles comprises: one (or more) lipid(s) whose melting point(s) is (are) substantially above room temperature; in combination with, one (or more) lipid(s) whose melting point(s) is (are) substantially less than room temperature.

Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.

Abstract: A process for the preparation of an oral disintegrating tablet comprising the antihypertensive telmisartan and the tablet obtained by the process.

Abstract: A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.

Abstract: A method for manufacturing oil-in-water emulsions for parenteral administration as well as to the use of such emulsions in the treatment or prevention of malnutrition and/or a deficiency in essential fatty acids and/or EPA and DHA and or stroke, sepsis, Alzheimer's disease or cancer.

Abstract: A stable and safe skin antiseptic solution comprises chlorhexidine, pharmaceutically acceptable salts of chlorhexidine (e.g. chlorhexidine digluconate), or a mixture thereof, dimethyl lauramide/myristamide, and water. Said solution is essentially free of coconut oil diethanolamine concentrate (“cocamide DEA”), a known carcinogen. The active antiseptic ingredient, chlorhexidine (or its salts), is a di(4-chlorophenyldiguanido) compound. The functions of dimethyl lauramide/myristamide in said solution include, but not limited to, an aesthetics enhancer, a foam stabilizer, a solubilizer, and a fragrance. Said solution is specifically formulated to be safe with a reduced risk of carcinogenicity, and be capable of producing a stable and long lasting foam. The active antiseptic agent is evenly distributed in said solution and in said foam, respectively.

Abstract: Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided.

Abstract: The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.

Abstract: A pharmaceutical composition is provided that is useful to enhance the repair of articular cartilage, to treat a joint injury or to prevent, inhibit or treat osteoarthritis in a mammal. The composition may include an effective amount of an isolated protein that is a chemoattractant for chondrogenic progenitor cells and/or an effective amount of an isolated protein that is a chondro genic factor or a nucleic acid sequence that encodes a chondrogenic factor.

Abstract: Aggregates formed from one or both of chitosan and hyaluronan, suspended or otherwise dispersed in a liquid carrier are useful for treating joint or muscle distress in a subject, where the composition may include one or more pharmaceutically active agents and the composition in locally delivered to the joint or muscle by, for example, injection.

Abstract: Methods for making particulate material include providing a first solution comprising one or more solvents and an active agent, providing a second solution comprising an antisolvent, mixing the first solution with the second solution to form a mixture, atomizing the mixture with a gas to produce droplets, and drying the droplets by directing the droplets into a chamber for removal of the solvent and the antisolvent to produce solid particles. Various apparatuses for producing particulate material in this manner are also provided.

Abstract: The invention relates to solid medicinal forms containing at least one active ingredient and at least one pharmaceutically compatible, water soluble drying agent which is selected from the group consisting of trimagnesium dicitrate and/or calcium chloride, the solid medicinal form having a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less. The invention also relates to solid medicinal forms containing a moisture-sensitive active ingredient and trimagnesium dicitrate.

Abstract: Disclosed are pharmaceutical particulates which release a pharmaceutical compound into the colon following oral administration. A particulate comprises a core comprising a pharmaceutical compound, an inner coating surrounding the core, wherein the inner coating comprises a pharmaceutically acceptable polysaccharide that is susceptible to enzymatic digestion by one or more enzymes present colonic microflora, and an outer coating surrounding the inner coating, wherein the outer coating comprises a polymer which is stable at upper gastrointestinal pH but can dissolve at pH>6. The core of a particulate can further comprise an excipient such as a diluent, a binder, a disintegrant, a lubricant, a glidant or a combination thereof. Particulates can comprise pharmaceutical compounds for treating colonic diseases such as C. difficile infection, ulcerative colitis, colon cancer, and Crohn's disease.

Abstract: Disclosed herein a pharmaceutical composition comprising aprepitant a pharmaceutically acceptable salt thereof; at least one hydrocarbon derivative selected from among a fatty acid of 14 to 18 carbon atoms, and a fatty alcohol of 14 to 18 carbon atoms; and at least one selected from among polyoxyethyelene-type nonionic surfactant, sucrose fatty acid ester, and Macrogol 15 hydroxystearate. The pharmaceutical composition of the present disclosure can release aprepitant or a pharmaceutically acceptable salt thereof to effectively exert the pharmaceutical efficacy, and can be dissolved in a fasted state simulated gastrointestinal fluid so that it can be useful for study on the in vivo pharmacokinetic behavior of aprepitant.

Abstract: The present invention relates to a solid oral insulin composition comprising a salt of capric acid which enhances the bioavailability and/or the absorption of said acylated insulin in combination with a polyvinyl alcohol coating, which is soluble in aqueous media independent of pH.

Abstract: A novel chemically modified alginate hydrogel has been developed which combines an aromatic compound with a carbohydrate, where the aromatic compound is one or more amines combined with an alginate. The chemical structure of alginate is modified using different amines and different methods, including: (1) covalently bonding aminoethyl benzoic acid to the alginate backbone, and (2) oxidizing the vicinal diol in the alginate chain to an aldehyde before coupling to aminoethyl benzoic acid. Alternatively, the combined aromatic compound and carbohydrate can be a dopamine combined with the alginate.

Abstract: Disclosed herein are nano-encapsulated compositions and methods of preparing the same. The compositions may be obtained through electrospray and electrospin technologies. The nano-encapsulated composition exhibit improved pharmacokinetic properties.

Abstract: A method for preparation of cruciferin-coated chitosan particles as a carrier for encapsulation and delivery of heat, pH and/or protease-degradable hydrophilic or hydrophobic bioactive compounds.

Abstract: Disclosed herein is a transdermal delivery system comprising methylphenidate or its salt as an active ingredient. Also provided are methods of delivering a therapeutically effective amount of methylphenidate to a subject for the treatment of a disease condition. The disease condition includes a neurological condition such as Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD). Kits including the transdermal delivery system and methods of making and using the transdermal delivery system are also provided.

Abstract: The present invention provides methods for modulating the immune response of a subject to a therapeutic agent, the method comprising administering an effective amount of a triphenylethylene (TRIP) compound with an effective amount of the therapeutic agent. In particular embodiments, the TRIP compound enhances the immune response of the subject to the therapeutic agent. In some embodiments, the TRIP compound is administered in different dosing schedules to provide a biphasic immunomodulation effect.

Abstract: Methods and formulations for batch-mixing flavonoid tinctures and infusing the flavonoid batch-mixed tincture into a food, beverage, cosmetic or drug products with minimal or no effect on the alcohol by volume of the product, and to precisely deliver the desired mixture concentration of the flavonoids, is provided. A batch-mixed flavonoid tincture includes an amount of at least two individual flavonoid tinctures, each flavonoid tincture being a mixture of at least a flavonoid and a solvent. The batch-mixed tincture is added to various food and beverages, or alternatively directly administered to a human or animal, to make a bioavailable amount of flavonoids to be absorbed and metabolized by the body providing demonstrated health benefits.

Abstract: Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.

Abstract: Disclosed herein are methods for suppressing or inhibiting platelet aggregation in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of Physalin to alleviate or ameliorate symptoms associated with diseases, disorders, and/or conditions resulted from platelet aggregation. According to preferred embodiments, Physalin is applied as a coating on an implantable device, such as a stent or a catheter.